A Potential Pathway of Th2 Development during Primary Immune Response

IL-10 Pretreated Dendritic Cells Can Prime Naive CD4+ T Cells to Secrete IL-4
  • Liming Liu
  • Benjamin E. Rich
  • Junichi Inobe
  • Wunjun Chen
  • Howard L. Weiner
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 417)


Differential cytokine production (Thl versus Th2) by CD4+ T cells during an immune response plays an important role in determining the biological implications of the response. Th1 cells are characterized by the dominance of IFN-γ production while Th2 cells produce predominantly 1L-4. It is now well established that IL-12 is essential for the priming of Thl cytokine secreting T cells1 while IL-4 is critical in the priming of Th2 cytokine secreting T cells2. While it has been suggested that CD1 specific NK1.1 CD4+ T cells in the spleen3, or CD4- CD8-, TCRαβ+ T cells restricted by MHC class I4 might be the potential sources of IL-4 during primary immune responses, these have not been clearly demonstrated.


Dendritic Cell Primary Immune Response Dendritic Cell Preparation Peripheral Blood Dendritic Cell Control Dendritic Cell 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Hsieh, C.-S., S.E. Macatonia, C.S. Tripp, S.F. Wolf, A. O’Garra, and K.M. Murphy. 1993. Development of ThI CD4’ T cells through IL-12 produced by Listeria -induced macrophages. Science (Wash.DC) 260: 547.CrossRefGoogle Scholar
  2. 2.
    Seder, R.A., W.E.Paul, M.M.Davis, and B.F.D.T. Groth. 1992. The presence of Interleukin 4 during in vitro priming determines the lymphokine-producing potential of CD4+ T cells from T cell receptor transgenic mice. J. Exp. Med. 176: 1091–1098.PubMedCrossRefGoogle Scholar
  3. 3.
    Yoshimoto, T., and E.P. Paul. 1994. CD4pos. NKl.1pos T cells promptly produce interleukin 4 in response to in vivo challenge with anti-CD3. J. Exp. Med. 179: 1285–1295.PubMedCrossRefGoogle Scholar
  4. 4.
    Leite-de-Moraes, M.C., A. Herbelin, F. Machavoine, A. Vicari, J.M. Gombert, and M.D.M. Papiernik. 1995. MHC class I- selected CD4–CD8-TCR-alpha beta ` T cells are potential source of IL-4 during primary immune response. J. Immunol. 155: 4544–50.PubMedGoogle Scholar
  5. 5.
    Hosken, N.A., K. Shibuya, A.W. Heath, K.M. Murphy, and A. O’Garra. 1995. The effect of antigen dose on CD4. T helper cells phenotype development in a T cell receptor-a 3 transgenic model. J. Exp. Med. 182: 1579.PubMedCrossRefGoogle Scholar
  6. 6.
    Hsieh, C.-S., A.B. Heimberger, J.S. Gold, A. O’Garra, and K.M. Murphy. 1992. Differential regulation of T helper phenotype development by interleukin 4 and 10 in a(3 T cell-receptor transgenic system. Proc. Natl. Acad. Sci. USA 89: 6065.PubMedCrossRefGoogle Scholar
  7. 7.
    Swain, S.L., A.D. Weinberg, M. English, and G. Huston. 1990. IL-4 direct the development of Th2-like helper effectors. J. Immunol. 145: 3796–3806.PubMedGoogle Scholar
  8. 8.
    Bujdoso, R., J. Hopkins, B.M. Dutia, P. Young, and I. McConnell. 1989. Characterization of sheep afferent lymph dendritic cells and their role in antigen carriage. J. Exp. Med. 170: 1285.PubMedCrossRefGoogle Scholar
  9. 9.
    Macatonia, S.E., S.C. Knight, A.J. Edwards, S. Griffiths, and P. Fryer. 1987. Localisation of antigen on lymph node dendritic cells after exposure to the contact sensitizer fluorescein isothiocyanate. Functional and Morphological studies. J. Exp. Med. 166: 1654.PubMedCrossRefGoogle Scholar
  10. 10.
    Liu, L.M., and G.G. MacPherson. 1993. Antigen acquisition by dendritic cells: intestinal dendritic cells acquire antigen administered orally and can prime naive T cells in vivo. J. Exp. Med. 177: 1299–1307.CrossRefGoogle Scholar
  11. 11.
    Murphy, K., A. Ilcimberger and D. Loh. 1990. Induction by antigen of intrathymic apoptosis of CD4+CD8+TCR10 Thymocytes in vivo. Science. 250: 1720.PubMedCrossRefGoogle Scholar
  12. 12.
    O’Garra, A. 1995. Interleukin-10: an inhibitor of macrophage-dependent stimulation of Thl cells. Interleukin-10., ed. d.W.M.R.a.J.E.d. Vries, Chapter 6. R.G. Landes Company, Texas. 53–55 pp.Google Scholar
  13. 13.
    Macatonia, S.E., T.M. Doherty, S.C. Knight, and A. O’Garra. 1991 Differential effect of Interleukin-10 on dendritic cell-induced T cell proliferation and interferon-g production. J. Immunol. 150: 3755–65.Google Scholar
  14. 14.
    Buelens, C., F. Willems, A. Delvaux, G. Pierard, J.P. Delville, T. Velu, and M. Goldman. 1995. Interleukin10 differentially regulates B7–1 (CD80) and B7–2 (CD86) expression on human peripheral blood dendritic cells. European.Journal of Immunology 25, no. 9: 2668–72.PubMedCrossRefGoogle Scholar
  15. 15.
    Kawamura, T., and M. Furuc. 1995. Comparative analysis of B7–1 and B7–2 expression in Langerhans cells: differential regulation by T helper type 1 and T helper type 2 cytokines. European Journal of lmmnnology 25, no. 7: 1913–7.CrossRefGoogle Scholar
  16. 16.
    Freeman, G.J., V.A. Boussiotis, A. Anumanthan, G.M. Bernstein, X.-Y. Ke, P.D. Rennert, G.S. Gray, J.G. Gribben, and L.M. Nadler. 1995. B7–1 and B7–2 do not deliver identical costimulatory signals, since B7–2 but not B7–1 preferentially costimulates the initial production of IL-4. Immunity 2: 523–532.PubMedCrossRefGoogle Scholar
  17. 17.
    Kuchroo, V.K., M.P. Das, J.A. Brown, A.M. Ranger, S.S. Zamvil, R.A. Sobel, H.L. Weiner. N. Nabavi, and L.H. Glimcher. 1995. B7–1 and B7–2 costimulatory molecules activate differentially the Th I /Th2 developmental pathways: application to autoimmunc disease therapy. Cell. 80: 707–718.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1997

Authors and Affiliations

  • Liming Liu
    • 1
  • Benjamin E. Rich
    • 2
  • Junichi Inobe
    • 1
  • Wunjun Chen
    • 1
  • Howard L. Weiner
    • 1
  1. 1.Center for Neurologic DiseasesBrigham and Women’s Hospital and Harvard Medical SchoolBostonUSA
  2. 2.Harvard Skin Disease Research CenterBrigham and Women’s Hospital and Harvard Medical SchoolBostonUSA

Personalised recommendations